COMMUNIQUÉS West-GlobeNewswire
-
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
18/10/2024 - 22:01 -
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
18/10/2024 - 22:00 -
American Shared Hospital Services Announces Key Management Appointments
18/10/2024 - 20:58 -
“A meaningful first step in acknowledging decades of harm”: Lung Health Foundation Applauds Landmark $32.5 Billion Legal Settlement Against Tobacco Companies
18/10/2024 - 20:10 -
CVRx announces new CPT® Category I codes for Barostim
18/10/2024 - 20:08 -
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
18/10/2024 - 18:39 -
RAMSAY SANTE :Annual results at the end of June 2024
18/10/2024 - 17:35 -
RAMSAY SANTE : Résultats annuels au 30 juin 2024
18/10/2024 - 17:35 -
Advanced Care Group Expands Nationwide with Acquisition of 3D Medical Staffing and AI-Powered Recruiting Solutions
18/10/2024 - 17:00 -
ClinicPlast: Türkiye ranks in the top ten countries hosting patients from across the globe
18/10/2024 - 16:20 -
Universal Health Care, LLC Opening a New Path in Healthcare
18/10/2024 - 15:35 -
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
18/10/2024 - 15:06 -
Jean Health Announces Expansion into Australia: Solving Urgent Rural Maternity Care Needs
18/10/2024 - 14:39 -
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
18/10/2024 - 14:30 -
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
18/10/2024 - 14:30 -
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis
18/10/2024 - 14:30 -
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM
18/10/2024 - 14:30 -
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
18/10/2024 - 14:20 -
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
18/10/2024 - 14:00
Pages